Compare LOAN & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LOAN | ACET |
|---|---|---|
| Founded | 1989 | 1947 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.9M | 93.5M |
| IPO Year | 1999 | N/A |
| Metric | LOAN | ACET |
|---|---|---|
| Price | $4.78 | $0.54 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 40.1K | ★ 1.9M |
| Earning Date | 10-24-2025 | 11-05-2025 |
| Dividend Yield | ★ 9.85% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.46 | N/A |
| Revenue | ★ $7,138,128.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.47 | N/A |
| P/E Ratio | $10.09 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.29 | $0.45 |
| 52 Week High | $6.05 | $1.12 |
| Indicator | LOAN | ACET |
|---|---|---|
| Relative Strength Index (RSI) | 44.58 | 33.71 |
| Support Level | $4.64 | $0.53 |
| Resistance Level | $4.83 | $0.57 |
| Average True Range (ATR) | 0.14 | 0.05 |
| MACD | 0.04 | 0.00 |
| Stochastic Oscillator | 74.77 | 5.35 |
Manhattan Bridge Capital Inc is a real estate finance company taxed as a REIT that specializes in originating, servicing and managing a portfolio of first mortgage loans. The company offers short-term, secured, non-banking loans which may renew or extend, before or after their initial term expires, to real estate investors to fund their acquisition, renovation, rehabilitation or development of residential or commercial properties located in the New York metropolitan area, including New Jersey and Connecticut, and in Florida.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.